

Large Trials of Ant-Diabetic Therapy (Significant Differences Between Treatments are Highlighted in Bold)

Study	Population	Background Therapy	Intervention	Number of Patients	Duration (years)	Average HbA1c achieved	Severe 'opathies'			Stroke	MI	Death
							Retin	Nephr	Neur			
Rates per Annum												
DCCT 1993	Type I Primary	Diet	Lax Intense	730	6.5	9.1	2.4%	0.1%	??	0.1%	0.5%	0.1%
				711		7.4	1.1%	<0.1%		<0.1%	0.3%	0.1%
UKPDS 33 1998	Type II Primary	Diet	Conventional Intensive	1,138	10	7.9	0.4%	0.1%	??	0.5%	1.7%	1.9%
				2,729		7.0	0.3%	0.1%		0.6%	1.5%	1.8%
UKPDS 34 1998	Type II Primary	Diet	Diet Metformin	411	10	8.2	0.3%	0.1%	??	0.6%	1.8%	2.1%
				342		7.4	0.3%	0.1%		0.3%	1.1%	1.4%
ACTION	Type II	Diet	Lax Intense	5,123 5,128	3.5	7.5% 6.4%	??	??	??	0.4% 0.4%	1.1 1.5% !	1.1% 1.4% !
ADVANCE	Type II Secondary	Conventional	Conventional Intensive (Gliclazide)	5,569	5	7.3%	1.2%	1.0%	8%	0.8%	1.2%	1.8%
				5,571		6.5%	1.2%	0.8%	8%	0.8%	1.1%	1.5%
PROACTIVE	Type II Secondary	Oral drugs and insulin	Placebo Pioglitazone	2,633	3.0	7.6	NR	No effect	NR	1.5%	2.0%	2.4%
				2,605		7.0			1.2%	1.7%	2.3%	
RECORD	Type II Primary	Metformin or Sulphonylurea	Placebo Rosiglitazone	2,227	3.8	??	NR	NR	NR	NR	0.5%	1.0%
				2,220					0.6%	1.0%		

NR = not reported. Shaded boxes indicate significant harm. Bold figures reflect significant benefit. Crude annual rates have been calculated when not provided in the paper.